IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Overview

cited authors

Jotte, Robert M.; Cappuzzo, Federico; Vynnychenko, Ihor; Stroyakovskiy, Daniil; Abreu, Delvys Rodriguez; Hussein, Maen A.; Soo, Ross A.; Conter, Henry Jacob; Kozuki, Toshiyuki; Silva, Carlos; Graupner, Vilma; Sun, Shawn; Lin, Ray S.; Kelsch, Claudia; Kowanetz, Marcin; Tien Hoang; Sandler, Alan; Socinski, Mark A.

authors

Socinski, Mark A., MD

Publication Date

June 20, 2018

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.